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TNF-a and IL-1b–mediated regulation of MMP-9 and TIMP-1
in renal proximal tubular cells.
Background. Tubulointerstitial fibrosis is a morphologic hall-
mark of chronic kidney disease and is a key factor in the pre-
diction of progression to end-stage renal failure. Disruption
of tubular basement membrane and interstitial extracellular
matrix (ECM) via cytokine-induced alterations in matrix met-
alloproteinases (MMPs), and tissue inhibitors of metallopro-
teinases (TIMPs) may be an important mechanism in this
process. The presence of the proinflammatory cytokines tumor
necrosis factor-a (TNF-a) and interleukin-1b (IL-1b) and their
effects on proximal tubular cells may be critical in this process.
Methods. Human proximal tubular cells were cultured in hor-
monally defined medium. Cells at 80% confluency were exposed
to TNF-a (0.1 to 100 ng/mL) or IL-1b (0.1 to 100 ng/mL) or a
combination of both for 48 hours. Activity and expression of
MMP-9 was examined by gelatin zymography and Western blot
analysis. TIMP-1 expression was analyzed by Western blotting.
Signaling through cytokine receptors, protein kinase C (PKC)
and mitogen-activated protein kinase (MAPK) pathways was
investigated.
Results. TNF-a but not IL-1b resulted in a dose-dependent
increase in the latent form of MMP-9. TIMP-1 was decreased by
treatment with either TNF-a or IL-1b . Cotreatment with IL-1b
abolished the induction of MMP-9 but augmented the inhibition
of TIMP-1 in the presence of TNF-a. Inhibition of PKC pro-
vided evidence of the importance of this pathway in mediating
the cytokine-induced suppression of TIMP-1 in human kidney
(HK-2) cells. Activation of the extracellular signal-regulated
protein kinase (ERK1/2) MAPK mediated the up-regulation
of MMP-9 by TNF-a whereas p38 was found to be involved in
the IL-1b–mediated inhibition of TNF-a–stimulated MMP-9.
Conclusion. The differential effects of TNF-a and IL-1b on
proximal tubular MMP-9 and TIMP-1 expression are mediated
through the TNF-RI, the IL-1-RI and the different signaling
pathways of PKC, ERK1/2, and p38 MAPK. These findings may
provide new insights into the role of proinflammatory cytokines
TNF-a and IL-1b in the development and possible therapeutic
intervention in tubulointerstitial fibrosis.
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Human glomerulonephritis remains one of the most
important causes of end-stage renal disease (ESRD)
worldwide. While the initial events triggering the devel-
opment of various forms of primary glomerulonephritis
vary somewhat, in the early phases all glomerulonephri-
tis are characterized by an inflammatory process medi-
ated by a cascade of soluble factors released by activated
resident cells and/or by infiltrating immune cells [1]. The
expression of growth factors and cytokines such as tu-
mor necrosis factor-a (TNF-a), interleukin-1b (IL-1b),
and transforming growth factor-b (TGF-b) has been
demonstrated in both experimental and human glomeru-
lonephritis [2]. The presence of these factors, while the
renal inflammatory process persists, leads to the devel-
opment of interstitial fibrosis [3], characterized by ex-
pansion of both the tubular basement membrane and the
interstitial extracellular matrix (ECM) [4]. Alterations
in matrix metabolism in both the tubular epithelial cells
and the interstitial fibroblasts results in imbalances be-
tween the rates of ECM production and activation of the
proteolytic enzymes, which function to degrade matrix
components [5, 6].
The matrix metalloproteinases (MMPs) are a large
family of zinc requiring proteolytic enzymes capa-
ble of degrading the macromolecules of the ECM.
Based on structure similarities and substrate specificity,
MMPs are divided into subclasses, including collagenases,
stromelysins, metalloelastases, membrane-type MMPs
(MT-MMPs), and gelatinases. All members of this family
share amino acid sequences and various structural do-
mains and are secreted as zymogens requiring activation
for proteolytic activity.
The gelatinases, MMP-2 (72 kD) and MMP-9 (92 kD)
are of crucial importance to the fibrotic process, given
their proteolytic activities toward basement membrane
components, laminin, and type IV collagen. It has been
shown that increased plasma levels of MMP-9 pre-
cede the appearance of microalbuminuria in noninsulin-
dependent diabetes mellitus [7]. Increased levels of MMP
are usually associated with disease activity and the influx
of inflammatory cells, and it is generally considered that
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both the level and duration of MMP elevation determine
the extent of renal damage [8]. The fact that MMP expres-
sion contributes to renal disease progression is attested
by the protective effect of MMP inhibitors on glomeru-
lar lesions, proteinuria and matrix accumulation in Thy
1.1 nephritis in rats, a model of proliferative mesangial
glomerulonephritis [9].
Naturally occurring inhibitors, tissue inhibitors of
metalloproteinases (TIMPs), are important controlling
factors in the actions of MMPs in normal and disease pro-
cesses. Four distinct TIMP molecules (TIMP-1, TIMP-2,
TIMP-3, and TIMP-4) have been isolated, cloned, and
characterized in several species [10–12]. TIMP-1, a glyco-
protein with an apparent molecular size of 30 kD appears
to be the major inhibitor and forms a 1:1 complex with
activated interstitial collagenase (MMP-1), stromelysin
(MMP-3), MMP-2, MMP-9, and pro-MMP-9 in a nonco-
valent fashion.
While it has been established in many cell types that
most MMPs are expressed on demand through the actions
of cytokines [13], very little work has been reported in
proximal tubular cells. The proximal tubular cell may play
a key role in the development of renal fibrosis. Progres-
sion of renal disease has been shown to be correlated with
tubulointerstitial involvement [14]. Furthermore, there
are very few reports on the effects of combinations of
cytokines on either MMPs or TIMPs. The in vivo situa-
tion during inflammatory events involves combinations
of cytokines. In this study, we focused on the possible in-
teractions of TNF-a and IL-1b in altering the expression
of MMP-9 and TIMP-1 in human proximal tubular cells.
Differential regulation of MMP-9 and TIMP-1 by combi-
nations of TNF-a and IL-1b was further investigated by
probing the receptors and signaling pathways involved
including the p42/44 and p38 mitogen-activated protein
kinase (MAPK) pathways and the role of protein kinase
C (PKC).
METHODS
Cell culture
The immortalized human kidney (HK-2) cell line used
during this work is of proximal tubule origin and was orig-
inally isolated from a normal human kidney [15]. The cell
line was obtained from the American Type Culture Col-
lection CRL-2190. HK-2 cells were maintained in 1:1 Del-
becco’s modified Eagle’s medium (DMEM):Hams F-12
(Promocell, Heidelberg, Germany) supplemented with
insulin (5 lg/mL), transferrin (5 lg/mL), sodium selenite
(5 ng/mL), hydrocortisone (36 ng/mL), epidermal growth
factor (EGF) (10 ng/mL), tri-iodothyronine (4 pg/mL),
2 mmol/L glutamine, and 100 U/mL penicillin and
100 lg/mL streptomycin.
The primary cells used during this work were obtained
from proximal tubular fragments of several different kid-
ney sections as described previously [16]. Several primary
cell lines were developed for experimental use. The cells
were maintained in specially formulated glucose-free 1:1
DMEM/Hams F-12 (Promocell) supplemented with 10%
fetal calf serum (FCS), 2 mmol/L L-glutamine, 10 mmol/L
sodium pyruvate, 100 U/mL penicillin, and 100 lg/mL
streptomycin. Cells were characterized as proximal tubu-
lar in origin using morphologic, immunologic, and func-
tional techniques [16].
Culture medium was changed every other day. Cells
were grown to confluency in 75 cm2 Costar flasks and
maintained at 37◦C in a humidified atmosphere contain-
ing 95% air:5% CO2. When cells reached the degree
of confluency required, they were trypsinized to form a
single cell suspension using a trypsin/ethylenediamine-
tetraacetic acid (EDTA) mixture in DMEM. Disassoci-
ated cells were harvested by centrifugation at 1200g for
3 minutes in a bench top centrifuge and seeded at an ap-
propriate density.
Materials and cell treatment
TNF-a and IL-1b (R&D Systems Europe, Oxford UK)
were prepared as stock solutions (10 lg/mL) by dissolving
the powder in sterile 0.1% bovine serum albumin (BSA).
Stock solutions of anti-TNF receptor I (TNF-RI) (R&D
Systems Europe) (500 lg/mL) and IL-1 receptor antago-
nist (R&D Systems Europe) (500 lg/mL) were prepared
in sterile phosphate-buffered saline (PBS). Bisindolyl-
maleimide I GF109203X (Calbiochem, Nottingham, UK)
was prepared as a stock solution of 1 mmol/L by dissolv-
ing the orange powder in dimethyl sulfoxide (DMSO)
and stored at −20◦C in aliquots. SB203580 (Calbiochem)
and PD98059 (Calbiochem) were prepared as stock so-
lutions of 10 mmol/L in DMSO and stored in aliquots at
−20◦C in the dark. Human antimouse MMP-9 and TIMP-
1 antibodies were obtained from R&D Systems Europe.
Human anti-phospho and whole cell p38 and p42/42
antibodies (Cell Signaling Technologies) were used ac-
cording to the manufacturer’s instructions. Cells were
preincubated with all inhibitors for 1 hour prior to in-
cubation with cytokines for 48 hours. All stock solutions
were diluted with medium to give the working concen-
trations just prior to use.
Cell viability
Incorporation of 3-(4,5-dimethylthiazol-2yl)-2,5-
diphenyl-tetrazolium bromide (MTT) (Sigma, Dublin,
Ireland) into the cells was measured as described by
Mosmann [17]. Cells were grown in 6-well plates, treated
for the appropriate time and then washed three times
with PBS. Cell monolayers were incubated for 3 hours
at 37◦C with 100 lL of 5 mg/mL MTT stock in PBS per
1 mL of DMEM. The dye was then aspirated off and the
blue-colored formazan product was extracted from the
cells by addition of 500 lL of DMSO and gentle agitation
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with a pipette tip. Absorption was measured at 600 nm
and viability was expressed as a % of the absorbance
recorded for control wells.
Detection of secreted gelatinase activity
HK-2 cells and primary proximal tubular cells were
grown on 6-well plates (Nunc, Bio-Sciences, Dublin, Ire-
land). At 80% confluency cells were treated appropri-
ately for various time periods. The conditioned medium
was collected and centrifuged at 800g for 5 minutes. The
cells were trypsinized and counted. Sample volumes were
corrected for cell number. The supernatants were then
concentrated 20-fold in centricon 30 microconcentrators.
Enzyme activity in the culture medium was monitored
by gelatin zymography as described previously [18, 19].
Briefly, 10 lL aliquots were mixed with an equal vol-
ume of nonreducing Laemmli sample buffer [20] and
electrophoresed in 7.5% sodium dodecyl sulfate (SDS)-
polyacrylamide gels containing 1 mg/mL gelatin. After
electrophoresis, the gels were cleared of SDS by incubat-
ing for 1 hour with two changes of 2.5% (vol/vol) Tri-
ton X-100. Gels were then incubated overnight at 37◦C
in substrate buffer (Tris-HCl 50 mmol/l, pH 7.5, CaCl2
10 mmol/L, NaCl 50 mmol/L, and 0.05% Brij 35). The
gels were then stained with Coomasie blue, destained,
and dried. Proteins with gelatinolytic activity were visu-
alized as areas of lytic activity on an otherwise blue back-
ground. Conditioned medium from HL60 cells treated
with 3 mmol/L phorbol 12-myristate 13-acetate (PMA)
was used as a positive control.
Preparation of cellular lysates for p44/42 and p38 analysis
Cells were cultured on 6-well plates. At 80% con-
fluency, cells were treated appropriately for 48 hours.
Cells were washed in ice-cold PBS and lysed by adding
150 lL of SDS sample buffer [62.5 mmol/L Tris-HCl, pH
6.8, 2% (wt/vol) SDS, 10% glycerol, 50 mmol/L dithio-
threitol (DTT), and 0.1%(wt/wt) bromophenol blue] to
each well of the plate. The cells were detached by scrap-
ing, transferred to Eppendorf tubes, and maintained on
ice at all times. Samples were sonicated for 10 seconds
and then allowed to boil for 5 minutes. Finally the samples
were centrifuged at 12,000g for 5 minutes and stored at
−20◦C until required. Just prior to electrophoresis, sam-
ples were boiled for 5 minutes.
Preparation of conditioned media for MMP-9 and
TIMP-1 proteins
Following the appropriate treatment, conditioned
media from HK-2 cells cultured on 6-well plates was re-
moved and concentrated 20-fold in centricon 30 micro-
concentrators.
SDS-polyacrylamide gel electrophoresis (PAGE). The
procedure used was that of Laemmeli [20], in which mul-
tiple protein samples were electrophoresed on a thin
slab of polyacrylamide gel. Twenty microliters of sam-
ple was added to 10 lL of 3 × sample buffer [2% SDS,
10% (vol/vol) glycerol, 60 mmol/L Tris-HCl, and 0.05%
(wt/vol) bromophenol blue, pH 6.8]. Proteins were then
denatured by boiling at 100◦C for 5 minutes.
Western blot analysis. Following electrophoresis, an
unstained gel was soaked in transfer buffer [48 mmol/L
Tris, 39 mmol/L glycine, 20% (vol/vol) MeOH, and
0.037% (wt/vol) SDS, pH 8.3) for 5 minutes. The pro-
teins within the gel were then transferred to nitrocellulose
membrane (0.2 lm pore size) using a semidry transfer
system at 80 mA for 1 hour. Staining of the blots with
Ponceau-S-stain was performed to ensure proper trans-
fer of proteins. The blots for whole cell p42/p44, phos-
phorylated p42/44, whole cell p38, and phosphorylated
p38 were blocked for 2 hours at room temperature in
5% marvel, and incubated with their respective primary
antibodies overnight at 4◦C. The blots for MMP-9 and
TIMP-1 were blocked for 1 hour at room temperature
in 5% marvel and also incubated overnight with their
respective antibodies. All secondary antibodies used in
Western blot analysis were horseradish peroxidase con-
jugated and were incubated with the blots for 30 min-
utes. The presence of bound antibody was detected using
a chemiluminescence blotting system with the substrate
luminol (Boehringer Mannheim, East Sussex, UK).
RESULTS
Exogenously applied TNF-a induced the expression of
92 kD MMP-9 in human proximal tubular cells
To examine the possible effects of TNF-a and IL-1b on
gelatinase expression in human proximal tubular cells, the
HK-2 cell line was treated with a range of concentrations
of the cytokines (0.1 to 100 ng/mL) for periods of 24 to
72 hours. Gelatin substrate zymography of conditioned
media showed that in the absence of exogenous cytokine,
HK-2 cells only produced a very moderate gelatinolytic
activity at a mass of 72 kD corresponding to the uncleaved
or proform of MMP-2 (Fig. 1A). The addition of TNF-a,
however, induced a dose (0.1 to 100 ng/mL)-dependent
increase in the production of the 92 kD (MMP-9) but
not the 72 kD gelatinolytic activity. The results for the
48-hour exposure are shown in Figure 1A and B. Similar
results were obtained at the 24- and 72-hour time expo-
sures (data not shown). Similar results were also obtained
with the primary renal proximal tubular cells (Fig. 2).
In contrast, the addition of IL-1b (0.1 to 100 ng/mL) on
its own for time periods up to 72 hours had no signifi-
cant effect on the secretion of the 92 kD MMP-9 or the
72 kD gelatinase (results for 48 hour exposure are shown
in Figure 1C and D). Similar results were also obtained
with the primary renal proximal tubular cells (Fig. 2).
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Fig. 1. Expression of matrix metalloproteinase (MMP-9) by human
kidney (HK-2) cells following tumor necrosis factor-a (TNF-a) and
interleukin-1b (IL-1b) treatment for 48 hours. HK-2 cells grown to 80%
confluency were treated with TNF-a or IL-1b alone (0.1 to 100 ng/mL)
or in combination for 48 hours. (A) and (C) Gelatinolytic activity in
the culture medium was detected by electrophoresis at 4◦C in a 7.5%
(wt/vol) acrylamide gel copolymerized with gelatin at a final concen-
tration of 1 mg/mL. After electrophoresis, the gels were washed for
1 hour at room temperature in 2.5% (vol/vol) Triton X-100 and incu-
bated overnight at 37◦C in incubation buffer. Clear zones of gelatin
lysis against blue background following Coomasie Brilliant Blue stain-
ing indicated the presence of gelatinolytic enzymes. Representative
gelatin gel following TNF-a treatment (A) and following IL-1b treat-
ment (C). Positive control indicates HL60 cells treated with phorbol
12-myristate 13-acetate (PMA) (3 lmol/L). (B and D) For Western blot
analysis supernatants were separated on a 7.5% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) gel and an unstained
gel transferred to nitrocellulose membrane. MMP-9 was detected using
monoclonal human anti-MMP-9 antibodies and antimouse conjugated
secondary antibodies. Bands corresponding to the molecular weight
of MMP-9 were detected as indicated by arrow. The blots shown are
representative of at least three independent experiments performed in
duplicate.
IL-1b antagonized the inductive effect of TNF-a on
92 kD MMP-9 production
We also examined the combined effect of TNF-a and
IL-1b on the production of 92 kD gelatinase in human
proximal tubule cells. At the optimal stimulatory concen-
tration of TNF-a (10 ng/mL), coincubation of HK-2 cells
MMP-9
92 kD
Po
siti
ve
co
ntr
ol
Co
ntr
ol
TN
F-α
 10
IL-
1β 1
0
TN
F-α
 10
IL-
1β 1
0
Fig. 2. Expression of matrix metalloproteinase (MMP-9) by primary
tubular epithelial cells following tumor necrosis factor-a (TNF-a) and
interleukin-1b (IL-1b) treatment for 48 hours. Primary tubular epithe-
lial cells grown to 80% confluency were treated with TNF-a or IL-1b
alone (0.1 to 100 ng/mL) or in combination for 48 hours. Gelatinolytic
activity in the culture medium was detected by electrophoresis at 4◦C
in a 7.5% (wt/vol) acrylamide gel copolymerized with gelatin at a final
concentration of 1 mg/mL. After electrophoresis, the gels were washed
for 1 hour at room temperature in 2.5% (vol/vol) Triton X-100 and incu-
bated overnight at 37◦C in incubation buffer. Clear zones of gelatin lysis
against blue background following Coomasie Brilliant Blue staining in-
dicated the presence of gelatinolytic enzymes. Representative gelatin
gel following TNF-a treatment and following IL-1b treatment. Pos-
itive control indicates HL60 cells treated with phorbol 12-myristate
13-acetate (PMA) (3 lmol/L). Bands corresponding to the molecular
weight of MMP-9 were detected as indicated by arrow. The blots shown
are representative of at least three independent experiments performed
in duplicate.
with IL-1b (10 ng/mL) completely abolished the 92 kD
MMP-9 activity (results for 48 hours shown in Fig. 1A).
This unexpected inhibitory effect of IL-1b was evident at
all three time points tested (24, 48, and 72 hours; data for
24 and 72 hours not shown). The nature of the gelatinase
identified by zymography as being 92 kD or pro-MMP-
9 was confirmed, using a Western blotting technique on
supernatants from cytokine-treated cells. A positive con-
trol, the HL60 cell line stimulated with 3 lmol/L PMA was
used. A dose (0.1 to 100 ng/mL) dependent up-regulation
of a 92 kD band reacting with the anti-MMP-9 anti-
body was observed following stimulation with TNF-a for
48 hours (Fig. 1B). Similar results were also obtained with
the primary renal proximal tubular cells (Fig. 2). Corre-
sponding to that observed in zymography, IL-1b alone
did not induce the 92 kD (Fig. 1D) band but did signifi-
cantly inhibit the TNF-a–induced pro-MMP-9 at 48 hours
(Fig. 1B).
TNF-a and IL-1b inhibited TIMP-1 production by
the HK-2 cells
Given the importance of TIMPs on the biologic activity
of MMPs, the influence of TNF-a and IL-1b on TIMP-1
protein expression was examined. Western blot analy-
sis revealed that a 30 kD band relating to TIMP-1 pro-
tein was relatively abundant in the concentrated medium
conditioned by HK-2 cells in the absence of exogenously
applied cytokines for 48 hours (Fig. 3A and B). TIMP-
1 production was, however, significantly decreased in a
dose-dependent manner following treatment with TNF-
a (0.1 to 100 ng/mL) (Fig. 2A) or IL-1b (0.1 to 100 ng/mL)
(Fig. 3B) for 48 hours. Costimulation of cells with both
TNF-a (10 ng/mL) and IL-1b (10 ng/mL) had an additive
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Fig. 3. Effect of tumor necrosis factor-a (TNF-a) and interleukin-1b
(IL-1b) on tissue inhibitors of metalloproteinase (TIMP-1) protein ex-
pression in human kidney (HK-2) cells at 48 hours. HK-2 cells grown
to 80% confluency were treated with TNF-a or IL-1b alone (0.1 to 100
ng/mL) or in combination for 48 hours. Supernatants were separated
on a 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) gel and an unstained gel transferred to nitrocellulose
membrane. TIMP-1 was detected using human monoclonal anti-TIMP-
1 antibodies and antimouse-conjugated secondary antibodies. Bands
corresponding to the molecular weight of TIMP-1 (28 kD) were de-
tected as indicated by arrow. (A) Representative Western blot follow-
ing TNF-a treatment. (B) Representative blot showing the effect of
IL-1b treatment. The blots shown are representative of at least three
independent experiments performed in duplicate.
effect leading to a further inhibition of TIMP-1 protein
production compared to either cytokine on its own at
10 ng/mL concentration (Fig. 3A and B).
TNF-a induced 92 kD MMP-9 and inhibited TIMP-1
expression through activation of the TNF-RI
The importance of the TNF-RI in mediating the TNF-
a–induced changes in MMP-9 and TIMP-1 was evalu-
ated following incubation of HK-2 cells with a TNF-RI
blocking antibody (100 ng/mL) both prior to and during
treatment with TNF-a (10 ng/mL) for 48 hours. Block-
ade of the receptor not only prevented the up-regulation
of MMP-9 (Fig. 4A) but also reduced the inhibitory ef-
fect of TNF-a on TIMP-1 (Fig. 4B). The effect of IL-1b
in inhibiting TIMP-1 expression was still evident in the
presence of the TNF-RI blocking antibody (Fig. 4B).
An IL-1 receptor antagonist (IL-1Ra) prevented
IL-1b–mediated inhibition of TNF-a-stimulated
MMP-9 and TIMP-1 suppression
The inhibition of IL-1b receptor signaling with a sol-
uble IL-1Ra (100 ng/mL) completely abolished the in-
hibitory effect of IL-1b on MMP-9 stimulation by TNF-a
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Fig. 4. Effect of the tumor necrosis factor receptor blocker (TNF-RI)
blocking antibody (TNF-RI Ab) on cytokine-induced alterations in
matrix metalloproteinase (MMP-9) and tissue inhibitor metallopro-
teinase (TIMP-1) protein expression in human kidney (HK-2) cells.
HK-2 cells grown to 80% confluency were pretreated for 1 hour with
TNF-RI blocking antibodies (100 ng/mL), and then incubated in the
presence or absence of TNF-a alone (10 ng/mL), or in combination
with interleukin-1b (IL-1b) (10 ng/mL) for 48 hours. (A) For MMP-9
analysis supernatants were separated on a 7.5% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) gel and an unstained
gel transferred to nitrocellulose membrane. MMP-9 was detected us-
ing monoclonal anti-MMP-9 antibodies and antimouse-conjugated sec-
ondary antibodies. Bands corresponding to the molecular weight of
MMP-9 (92 kD) were detected as indicated by arrow. (B) For TIMP-
1 detection supernatants were separated on a 12% SDS-PAGE gel
and an unstained gel transferred to nitrocellulose membrane. TIMP-1
was detected using monoclonal anti-TIMP-1 antibodies and antimouse-
conjugated secondary antibodies. Bands corresponding to the molecu-
lar weight of TIMP-1 (28 kD) were detected as indicated by arrow. The
blots shown are representative of at least three independent experi-
ments performed in duplicate.
(Fig. 5A). In addition, the additive suppression of TIMP-
1 by IL-1b following TNF-a and IL-1b cotreatment was
reduced following coincubation with IL-1Ra (Fig. 5B).
PKC was not involved in 92 kD MMP-9 production
but played an important role in cytokine-mediated
TIMP-1 suppression in HK-2 cells
In this study, the selective cell permeable, PKC in-
hibitor, bisindolylmaleide I (GF109203X) (10 lmol/L),
was used to determine the involvement of this pathway
in mediating the 92 kD MMP-9 production in HK-2 cells
following TNF-a stimulation. GF109203X was found to
have no significant effect alone and it did not inhibit the
TNF-a-induced increase in pro-MMP-9 protein produc-
tion at 48 hours (Fig. 6A). Similarly, the abolition of TNF-
a–induced increase in pro-MMP-9 following cotreatment
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Fig. 5. Effect of the interleukin-1 (IL-1) receptor antagonist (IL-1Ra)
on cytokine-induced alterations on matrix metalloproteinase (MMP-9)
and tissue inhibitors of metalloproteinase (TIMP-1) expression in hu-
man kidney (HK-2) cells. HK-2 cells grown to 80% confluency were
pretreated for 1 hour with the IL-1Ra (100 ng/mL), and then incubated
in the presence or absence of tumor necrosis factor-a (TNF-a) alone
(10 ng/mL), or in combination with IL-1b (10 ng/mL) for 48 hours.
(A) Gelatinolytic activity in the culture medium was detected by elec-
trophoresis at 4◦C in a 7.5% (wt/vol) acrylamide gel copolymerized with
gelatin at a final concentration of 1 mg/mL. After electrophoresis, the
gels were washed for 1 hour at room temperature in 2.5% (vol/vol) Tri-
ton X-100 and incubated overnight at 37◦C in incubation buffer. Clear
zones of gelatin lysis against blue background following Coomasie Bril-
liant Blue staining indicated the presence of gelatinolytic enzymes. (B)
For TIMP-1 detection supernatants were separated on a 12% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel
and an unstained gel transferred to nitrocellulose membrane. TIMP-1
was detected using monoclonal anti-TIMP-1 antibodies and antimouse-
conjugated secondary antibodies. Bands corresponding to the molecu-
lar weight of TIMP-1 (28 kD) were detected as indicated by arrow. The
blots shown are representative of at least three independent experi-
ments performed in duplicate.
with IL-1b was also unaffected by blocking the PKC path-
way. In marked contrast to this, the cytokine-mediated
suppression of TIMP-1 observed following treatment
with TNF-a alone or in combination with IL-1b was
shown to be dependent upon signaling through PKC
(Fig. 6B). In the presence of GF109203X, neither TNF-a
nor IL-1b were effective in blocking TIMP-1 production
(Fig. 6B).
TNF-a and IL-1b stimulated the phosphorylation of
p38 and extracellular-regulated protein kinase (ERK1/2)
MAPK in HK-2 cells at 48 hours
In order to elucidate the role of distinct MAPK in
cytokine-mediated alterations in 92 kD MMP-9 and
TIMP-1 we determined the activation of ERK1/2 and
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Fig. 6. Effect of the protein kinase C (PKC) inhibitor GF109203X
(GFX) on the cytokine-induced alterations in matrix metalloproteinase
(MMP-9) and tissue inhibitors of metalloproteinase (TIMP-1) protein
expression in human kidney (HK-2) cells. HK-2 cells grown to 80%
confluency were pretreated for 1 hour with GFX (10 lmol/L), then
in the presence or absence of tumor necrosis factor-a (TNF-a) alone
(10 ng/mL), or in combination with interleukin-1b (IL-1b) (10 ng/mL)
for 48 hours. (A) For MMP-9 analysis supernatants were separated on a
7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) gel and an unstained gel transferred to nitrocellulose mem-
brane. MMP-9 was detected using monoclonal anti-MMP-9 antibodies
and antimouse-conjugated secondary antibodies. Bands corresponding
to the molecular weight of MMP-9 (92 kD) were detected as indicated
by arrow. (B) For TIMP-1 detection supernatants were separated on
a 12% SDS-PAGE gel and an unstained gel transferred to nitrocellu-
lose membrane. TIMP-1 was detected using monoclonal anti-TIMP-1
antibodies and antimouse-conjugated secondary antibodies. Bands cor-
responding to the molecular weight of TIMP-1 (28 kD) were detected
as indicated by arrow. The blots shown are representative of at least
three independent experiments performed in duplicate.
p38 by Western blot analysis using antibodies specific
for phosphorylated activated forms of these MAPKs.
Dual phosphorylation on specific tyrosine and threonine
residues is characteristic of p38 MAPK activation. For
this reason p38 MAPK activation (phosphorylation) was
detected using a phospho-specific p38 MAPK antibody
that recognizes p38 dually phosphorylated at threonine
180 and tyrosine 182. In order to control for cytokine-
induced changes in p38 kinase, whole cell p38 MAPK
expression was also examined.
Treatment with TNF-a, IL-1b , or the p38 inhibitor
SB203580 both alone or in combination had no effect
on whole cell p38 MAPK expression at 48 hours (Fig. 7).
Both TNF-a (10 ng/mL) and IL-1b (10 ng/mL) alone,
however, caused significant increases over basal levels
of p38 MAPK phosphorylation, which was further aug-
mented following costimulation with both cytokines for
48 hours (Fig. 7). Incubation with the ERK1/2 MAPK
inhibitor PD98059 (10 lmol/L) also led to an increase
in the phosphorylation of p38 (Fig. 7B) indicating that
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Fig. 7. Effect of cytokines alone and in combination with SB203580
(SB) on p38 mitogen-activated protein kinase (MAPK) activation in
human kidney (HK-2) cells at 48 hours. Cells grown to 80% confluency
were pretreated for 1 hour with SB203580 (10 lmol/L), and then incu-
bated in the presence or absence of tumor necrosis factor-a (TNF-a) or
interleukin-1b (IL-1b) alone (10 ng/mL) or in combination for 48 hours.
Whole cell extracts subjected to sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (SDS-PAGE) and Western blotting were probed
with specific phosphorylated p38 and whole cell p38 antibodies. Bands
were visualized with enhanced chemiluminescence (ECL). (A and B)
Representative Western blots showing phosphorylated p38 and whole
cell p38 following TNF-a and IL-1b treatment, respectively. The blots
shown are representative of at least three independent experiments
performed in duplicate.
cross talk can occur between the p38 and ERK1/2 MAPK
pathways.
ERK1/2 (p42/44) activation may also be characterized
by dual phosphorylation. A phosphospecific antibody,
which recognizes ERK1/2 when phosphorylated on thre-
onine 202 and tyrosine 204, was used to detect kinase
activation. Whole cell ERK1/2 MAPK expression was
examined to control for cytokine-induced changes in the
protein content of the kinase. Whole cell ERK1/2 MAPK
kinase expression remained unchanged following treat-
ment with TNF-a, IL-1b , SB203580, or with PD98059
(an inhibitor which prevents activation of MEK1 by
upstream kinases), either alone or in combination for
48 hours (Fig. 8). Levels of ERK1/2 phosphorylation
were, however, significantly increased following treat-
ment with TNF-a (10 ng/mL) or IL-1b (10 ng/mL)
alone and following costimulation with both cytokines for
48 hours (Fig. 8). Pretreatment with the PD98059 com-
pound inhibited both the basal, TNF-a, and IL-1b-
stimulated ERK1/2 phosphorylation (Fig. 8). Incubation
with the p38 MAPK inhibitor SB203580 (10 lmol/L)
also led to an increase in the phosphorylation of p44/42
(Fig. 8B) indicating that cross-talk can occur between the
p38 and ERK1/2 MAPK pathways.
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Fig. 8. Effect of cytokines alone and in combination with PD98059 and
SB203580 on p42/p44 mitogen-activated protein kinase (MAPK) acti-
vation in HK-2 cells at 48 hours. Cells grown to 80% confluency were
pre-treated with PD98059 (10 lM) or SB203580 (10 lM) for 1 hour and
then incubated in the presence or absence of tumor necrosis factor-a
TNF-a alone (10 ng/mL), or IL-1b (10 ng/mL) alone or in combination
for 48 hours. Whole cell extracts subjected to SDS-PAGE and Western
blotting were probed with specific phosphorylated p42/p44 and whole
cell p42/p44 antibodies. The bands were visualized with ECL. (A and
B) Representative Western blots showing phosphorylated p42/44 and
whole cell p42/44 following TNF-a and IL-1b treatment, respectively.
The blots shown are representative of at least three independent exper-
iments performed in duplicate.
The up-regulation of 92 kD MMP-9 by TNFa involved
the ERK1/2 MAPK pathway whereas suppression by
IL-1b was mediated by p38 MAPK
In further experiments, we dissected the role of p38
and ERK1/2 signaling in the cytokine-mediated changes
in pro-MMP-9 and TIMP-1 in the HK-2 cells. Block-
ade of the p38 pathway with the inhibitor SB203580
(10 lmol/L) had no effect on basal 92 kD MMP-9 pro-
duction or on the TNF-a–induced increase following
48 hours’ treatment (Fig. 9). However, suppression by IL-
1b of the TNF-a–stimulated production of MMP-9 was
ameliorated to some extent by inhibition of the p38 path-
way (Fig. 9A). Inhibition of the ERK1/2 pathway had
a major impact in reducing the TNF-a–stimulated pro-
duction of MMP-9 (Fig. 9A). The suppression of TIMP-
1 following treatment with TNF-a or IL-1b remained
unaffected by treatment with SB203580 or PD98059
(Figs. 9B and 10B) indicating that the p38 and ERK1/2
pathways were not involved. Cellular viability was not
affected by any of the individual or combined treat-
ments with TNF-a, IL-1b , and inhibitors of the signaling
pathways.
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Fig. 9. Effect of the p38 inhibitor SB203580 (SB) on cytokine-induced
alterations in matrix metalloproteinase (MMP-9) and tissue inhibitors
of metalloproteinase (TIMP-1) protein expression in human kidney
(HK-2) cells. HK-2 cells grown to 80% confluency were pretreated for
1 hour with SB203580 (10 lmol/L), and then incubated in the presence
or absence of tumor necrosis factor-a (TNF-a) alone (10 ng/mL), or in
combination with interleukin-1b (IL-1b) (10 ng/mL) for 48 hours. (A)
For MMP-9 analysis supernatants were separated on a 7.5% sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel
and an unstained gel transferred to nitrocellulose membrane. MMP-9
was detected using monoclonal anti-MMP-9 antibodies and antimouse-
conjugated secondary antibodies. Bands corresponding to the molec-
ular weight of MMP-9 (92 kD) were detected as indicated by arrow.
(B) For TIMP-1 detection supernatants were separated on a 12% SDS-
PAGE gel and an unstained gel transferred to nitrocellulose membrane.
TIMP-1 was detected using monoclonal anti-TIMP-1 antibodies and
antimouse-conjugated secondary antibodies. Bands corresponding to
the molecular weight of TIMP-1 (28 kD) were detected as indicated by
arrow. The blots shown are representative of at least three independent
experiments performed in duplicate.
DISCUSSION
This report provides the first evidence that cytokines
can alter the production of pro-MMP-9 in human renal
proximal tubular cells. Untreated proximal tubular cells
in culture did not produce detectable MMP-9. The 72
kD form of MMP-2 was, however, visible in cultures of
proximal tubular cells in our experiments. Treatment with
TNF-a resulted in a time- and dose-dependent increase
in 92 kD MMP-9 production but MMP-2 production re-
mained unaffected. This is consistent with the view that
MMP-2 expression tends to be constitutive and is thought
to perform a surveillance function [21].
Among the cytokines involved in MMP regulation,
there is evidence to suggest that TNF-a may be crucial,
particularly with regard to MMP-9. In fact, TNF-a has
been demonstrated to markedly up regulate MMP-9 pro-
tein in human monocytes [22], endothelial cells [23], fi-
broblasts [24], leukemia cells [25], giant tumor stromal
cells [26], myometrial smooth muscle cells [27], and con-
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Fig. 10. Effect of the MEK1 inhibitor PD98059 (PD) on cytokine-
induced alterations in matrix metalloproteinase (MMP-9) and tissue
inhibitors of metalloproteinase (TIMP-1) protein expression in human
kidney (HK-2) cells. HK-2 cells grown to 80% confluency were pre-
treated for 1 hour with PD98059 (10 lmol/L), and then incubated in
the presence or absence of tumor necrosis factor-a (TNF-a) alone (10
ng/mL), or in combination with interleukin-1b (IL-1b) (10 ng/mL) for
48 hours. (A) For MMP-9 analysis supernatants were separated on a
7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) gel and an unstained gel transferred to nitrocellulose mem-
brane. MMP-9 was detected using monoclonal anti-MMP-9 antibodies
and antimouse-conjugated secondary antibodies. Bands corresponding
to the molecular weight of MMP-9 (92 kD) were detected as indicated
by arrow. (B) For TIMP-1 detection supernatants were separated on
a 12% SDS-PAGE gel and an unstained gel transferred to nitrocellu-
lose membrane. TIMP-1 was detected using monoclonal anti-TIMP-1
antibodies and antimouse-conjugated secondary antibodies. Bands cor-
responding to the molecular weight of TIMP-1 (28 kD) were detected
as indicated by arrow. The blots shown are representative of at least
three independent experiments performed in duplicate.
junctional fibroblasts [28]. Our results now indicate that
human proximal tubular cells also respond to TNF-a with
an increase in MMP-9.
However, the proinflammatory cytokine IL-1b did not
result in an increase in MMP-9 in HK-2 proximal tubular
cells. In fact, a most striking finding in the present study
was that TNF-a–induced increase in MMP-9 was sup-
pressed by cotreatment with IL-1b . We have verified this
unique finding in primary renal proximal tubular cells. In
different cell types it appears that the same cytokine can
have either an inducible or a suppressive effect on MMP
expression [29]. For instance, in human lung fibroblasts,
Sasaki et al [30] found that treatment with TNF-a or IL-
1b alone caused a significant reduction in MMP-9 activ-
ity. We have shown that the HK-2 cell line constitutively
secreted TIMP-1 and following treatment with either
TNF-a or IL-1b , TIMP-1 production was decreased in
both a time- and dose-dependent manner. Therefore,
in contrast to the opposing effects of TNF-a and IL-1b
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on MMP-9, these cytokines acted in a similar manner on
TIMP-1 expression.
In control of the degradation of the renal matrix, the
proximal tubular secretion of TIMP may be as important
as pro-MMP production. The influence of proinflamma-
tory cytokines, TNF-a and IL-1b on TIMP production
by fibroblasts of various origins has provided variable re-
sults, either stimulation [31] or suppression [32]. Thus the
expression of TIMP under cytokine stimulation may vary
according to the cell type and/or conditioned by other
agents, such as growth factors, possibly introduced in the
cultures by serum or other components of the media. It
should be noted that our experiments were carried out
in defined medium in the absence of serum. Our findings
in HK-2 cells show that when TNF-a was also present, it
down-regulated TIMP-1. Because TNF-a and IL-1b are
present in significant concentrations in many different
forms of inflammatory renal disease, it is possible that
these cytokines may exert different effects on MMP-9
expression and later activation may ultimately result in
basement membrane remodeling. We therefore decided
to explore the signaling pathways involved in the differ-
ential effects of TNF-a and IL-1b in human proximal
tubular cells.
The mechanism by which cytokines regulate MMP-9
and TIMP-1 expression has not been fully established.
The signal-inducing cascade initiated by the binding of
these cytokines to their receptors may be directly respon-
sible [21]. In this study we have shown that the effects
of TNF-a and IL-1b on MMP-9 and TIMP-1 in HK-2
cells are mediated through the TNF-RI and the IL-1-RI,
respectively. However, little information is available re-
garding the signal transduction mechanism controlling
MMP-9 and TIMP-1 production following the binding
of the cytokines to their receptors. There are some sim-
ilarities in the promoter regions of the human MMP-9
and TIMP-1 genes. The human MMP-9 gene has a 2.2 kb
promoter region, but the proximal 670 bp promoter se-
quence contains all the essential transcription-regulatory
components. Important cis-acting elements include two
activating protein-1 (AP-1) sites, nuclear factor-kappaB
(NF-jB), Sp1, GT box, and PEA3 elements. It is gener-
ally accepted that maximal induction of MMP-9 expres-
sion requires all three cis-acting elements, although the
proximal AP-1 site plays an indispensable role in MMP-9
gene transcription [33]. In the promoter of the TIMP-1
gene there is also an active AP-1 binding site [34]. The
transcription factor AP-1 is believed to be a major indi-
cator of activated PKC [35].
We first probed the role of PKC in pro-MMP-9 and
TIMP-1 expression and we found that PKC was not in-
volved in pro-MMP-9 production. Our results, in HK-2
cells, showing lack of effect of PKC on MMP-9 are simi-
lar to other reported results in myometrial smooth muscle
cells [27] and in human uterine cervical fibroblasts [23].
Cytokine-mediated up-regulation of MMP-9 expression
has been reported to be critically dependent on the ac-
tivation of NF-jB and AP-1 both binding to the corre-
sponding regulatory elements within the promoter region
of the MMP-9 gene [33]. Both transcriptional activators
are commonly activated following signaling by various
cytokines, including TNF-a and IL-1b . A prominent sig-
naling pathway that processes cytokine signals is that of
the MAPKs, an evolutionary highly conserved protein
family [36].
Our studies show that TNF-a and IL-1b both acti-
vate ERK1/2 in HK-2 cells. Blockade of ERK1/2 with
PD98059 resulted in a significant reduction of TNF-
a–stimulated MMP-9, indicating this pathway plays an
important role in MMP-9 up-regulation by TNF-a. In
contrast, the suppressive effect of IL-1b on TNF-a–
stimulated MMP-9, and the TNF-a and IL-1b mediated
reduction in TIMP-1 levels in HK-2 cells remained un-
affected by inhibition of MEK-1, suggesting the involve-
ment of other signaling pathways.
Our findings that TNF-a-stimulated MMP-9 produc-
tion in HK-2 cells involved signaling via ERK1/2 are con-
sistent with previous finings in some other cell types. In
human T lymphocytes, inhibition of Ha-Ras caused an in-
crease in fibronectin-induced MMP-9 expression suggest-
ing that inhibitory signals for the expression of this MMP
may be transduced through the Ras/Raf-1/MAPK path-
ways [37]. The Ras-MEK1-MAPK pathway was shown
to be critical for the activation of MMP-9 secretion and
invasiveness in a transformed rat fibroblast cell line [39].
Our observations are in accordance with other studies
with PD98059, demonstrating that the ERK1/2 pathway
mediates activation of MMP-1 expression in fibroblasts
[40] and MMP-9 expression in transformed keratinocytes
[38].
We have shown that the p38 MAPK plays an important
role in IL-1b–mediated suppression of TNF-a–induced
pro-MMP-9 in HK-2 cells. Both TNF-a and IL-1b were
shown to increase the phosphorylation of p38 in HK-2
cells following 48 hours’ treatment indicating activation
of this MAPK. p38 however does not appear to be in-
volved in either the TNF-a–mediated up-regulation of
pro-MMP-9 or in the suppression of TIMP-1 observed
following cytokine treatment. However, p38 was involved
in the IL-1b–mediated suppression of TNF-a–induced
MMP-9.
CONCLUSION
We have shown that TNF-a modulates ECM turnover
in the HK-2 human proximal tubule cell line by increasing
MMP-9 in addition to TIMP-1 suppression. However, a
striking finding was the effect of IL-1b in preventing the
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TNF-a–induced MMP-9 production. In contrast, IL-1b
acted in concert with TNF-a to reduce TIMP-1 produc-
tion. The effects of TNF-a and IL-1b in HK-2 cells were
mediated through the TNF-RI and the IL-1RI receptors.
Activation of PKC appeared to be critical in the TNF-a
and IL-1b–mediated decrease in TIMP-1. Activation of
both the ERK and p38 MAPK pathways occurs following
cytokine stimulation, indicating that these cascades reg-
ulate the activity of key transcription factors, such as c-
Jun or NF-jB, leading to cytokine-mediated MMP-9 and
TIMP-1 gene expression or repression depending on the
mediators present. Activation of ERK1/2 was shown to
be involved in the TNF-a induction of MMP-9, whereas
activation of p38 was shown to be involved in the inhibi-
tion by IL-1b of MMP-9 production. The different com-
binations of TNF-a and IL-1b present in inflammatory
renal disease may therefore influence disease outcome
depending on MMP-9 and TIMP-1 expression in proxi-
mal tubular cells. The present insights into the different
signaling mechanisms involved may provide opportuni-
ties to develop novel therapeutic approaches.
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